Azvudine hydrochloride
Based on 6 publication(s) in Google Scholar
Azvudine (RO-0622) hydrochloride is a potent nucleoside reverse transcriptase inhibitor (NRTI), with antiviral activity on HIV, HBV and HCV. Azvudine hydrochloride exerts highly potent inhibition on HIV-1 (EC50s ranging from 0.03 to 6.92 nM) and HIV-2 (EC50s ranging from 0.018 to 0.025 nM). Azvudine hydrochloride inhibits NRTI-resistant viral strains. Azvudine (hydrochloride) is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
For research use only. We do not sell to patients.
- Purity: 99.19%
- CAS No.: 1333126-31-0
- Formula: C9H12ClFN6O4
- Molecular Weight:322.68
-
Storage:
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Anti-Infection Compound Library
HY-L002
-
FDA-Approved Drug Library
HY-L022
-
Antiviral Compound Library
HY-L027
-
Drug Repurposing Compound Library
HY-L035
-
Glycoside Compound Library
HY-L042
-
Nucleotide Compound Library
HY-L044
-
NMPA-Approved Drug Library
HY-L053
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Anti-Hepatitis C Virus Compound Library
HY-L073
-
Anti-Drug-Resistant Compound Library
HY-L169
-
Multi-Target Compound Library
HY-L176
-
Bioactive Compound Library Max
HY-L181
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
Azide Compound Library
HY-L256
Publications Citing Use of MedChemExpress (MCE) Azvudine hydrochloride
More- Signal Transduct Target Ther. 2025 Jan 17;10(1):30. [Abstract]
- Acta Pharm Sin B. 2024 Jul;14(7):3140-3154. [Abstract]
- Biomed Pharmacother. 2025 May 27:188:118215. [Abstract]
- Mikrochim Acta. 2025 Dec 8;193(1):10. [Abstract]
- Antiviral Res. 2025 Jan 16:235:106081. [Abstract]
- NAR Mol Med. 2025 Aug 11;2(3):ugaf029. [Abstract]
Biological Activity
|
HIV-1 0.03-6.92 nM (EC50) |
HIV-2 0.018-0.02 nM (EC50) |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| ACH-2 cell line | IC50 |
0.11 μM
Compound: 11
|
Cytotoxicity activity against human ACH2 by CellTiter-Glo luminescent cell viability assay
Cytotoxicity activity against human ACH2 by CellTiter-Glo luminescent cell viability assay
|
[PMID: 21745701] |
| HEK-293T | IC50 |
>140 μM
Compound: 11
|
Cytotoxicity activity against human 293T by CellTiter-Glo luminescent cell viability assay
Cytotoxicity activity against human 293T by CellTiter-Glo luminescent cell viability assay
|
[PMID: 21745701] |
| HepG2 | IC50 |
>140 μM
Compound: 11
|
Cytotoxicity activity against human HepG2 by CellTiter-Glo luminescent cell viability assay
Cytotoxicity activity against human HepG2 by CellTiter-Glo luminescent cell viability assay
|
[PMID: 21745701] |
| MT2 | EC50 |
0.13 nM
Compound: 11
|
Antiviral activity against vesicular stomatitis virus G-pseudotyped Human immunodeficiency virus 1 NL4-3 infected in human MT2 cells assessed as inhibition of viral replication after 48 hrs by luciferase activity reporter gene assay
Antiviral activity against vesicular stomatitis virus G-pseudotyped Human immunodeficiency virus 1 NL4-3 infected in human MT2 cells assessed as inhibition of viral replication after 48 hrs by luciferase activity reporter gene assay
|
[PMID: 21745701] |
| MT4 | IC50 |
0.12 μM
Compound: 11
|
Cytotoxicity activity against human MT4 by CellTiter-Glo luminescent cell viability assay
Cytotoxicity activity against human MT4 by CellTiter-Glo luminescent cell viability assay
|
[PMID: 21745701] |
| PBMC | IC50 |
0.15 μM
Compound: 11
|
Cytotoxicity activity against human PBMC by CellTiter-Glo luminescent cell viability assay
Cytotoxicity activity against human PBMC by CellTiter-Glo luminescent cell viability assay
|
[PMID: 21745701] |
| TZM | IC50 |
>140 μM
Compound: 11
|
Cytotoxicity activity against human TZM-bl by CellTiter-Glo luminescent cell viability assay
Cytotoxicity activity against human TZM-bl by CellTiter-Glo luminescent cell viability assay
|
[PMID: 21745701] |
Azvudine (RO-0622) hydrochloride displays strong inhibition on wild-type HIV-1IIIB and HIV-1RF with an EC50 ranging from 30 to 110 pM. The EC50 values of Azvudine hydrochloride against HIV-1KM018, HIV-1TC-1 and HIV-1WAN T69N are 6.92, 0.34 and 0.45 nM, respectively. Azvudine is sensitive to NRTIs-resistant strain HIV-174V, PIs-resistant strains HIV-1L10R/M46I/L63P/V82T/I84V and HIV-1RF V82F/184V, and FIs-resistant strain pNL4-3gp41 (36G) V38A/N42T. The EC50 values of Azvudine hydrochloride against these resistant strains are 0.11, 0.14, 0.37 and 0.36 nM respectively[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 1333126-31-0
-
Appearance Solid
-
Molecular Weight 322.68
-
Formula C9H12ClFN6O4
-
Color Off-white to yellow
-
SMILES
O[C@@H]1[C@](CO)(N=[N+]=[N-])O[C@@H](N2C(N=C(N)C=C2)=O)[C@H]1F.Cl
-
Synonyms
RO-0622 hydrochloride; FNC hydrochloride
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (6)
-
Journal Impact Factor
-
Most Recent
-
Signal Transduct Target Ther
Real-world effectiveness and safety of oral azvudine versus nirmatrelvir‒ritonavir (Paxlovid) in hospitalized patients with COVID-19: a multicenter, retrospective, cohort study. [Abstract]2025 Jan 17;10(1):30. PMID: 39819859 -
Acta Pharm Sin B
Selectively T cell phosphorylation activation of azvudine in the thymus tissue with immune protection effect. [Abstract]2024 Jul;14(7):3140-3154. PMID: 39027259 -
Biomed Pharmacother
Azvudine exhibits potent differentiation-inducing effect by targeting the TERT/p21 axis in acute myeloid leukemia. [Abstract]2025 May 27:188:118215. PMID: 40435838 -
Mikrochim Acta
Strain-promoted azide-alkyne cycloaddition-based fluorometric detection of azvudine using DBCO-functionalized carbon dots. [Abstract]2025 Dec 8;193(1):10. PMID: 41359210 -
Antiviral Res
Metformin inhibits EV-A71 and CVA16 infections by regulating TRIB3-SCARB2 axis and activating AMPK. [Abstract]2025 Jan 16:235:106081. PMID: 39826812 -
NAR Mol Med
Mechanism and spectrum of inhibition of viral polymerases by 2'-deoxy-2'-β-fluoro-4'-azidocytidine or azvudine. [Abstract]2025 Aug 11;2(3):ugaf029. PMID: 40900943
Solvent & Solubility
H2O : 50 mg/mL (154.95 mM; Need ultrasonic)
DMSO : 25 mg/mL (77.48 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Purity & Documentation
-
Data Sheet (276 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO / H2O | 1 mM | 3.0990 mL | 15.4952 mL | 30.9905 mL | 77.4761 mL |
| 5 mM | 0.6198 mL | 3.0990 mL | 6.1981 mL | 15.4952 mL | |
| 10 mM | 0.3099 mL | 1.5495 mL | 3.0990 mL | 7.7476 mL | |
| 15 mM | 0.2066 mL | 1.0330 mL | 2.0660 mL | 5.1651 mL | |
| 20 mM | 0.1550 mL | 0.7748 mL | 1.5495 mL | 3.8738 mL | |
| 25 mM | 0.1240 mL | 0.6198 mL | 1.2396 mL | 3.0990 mL | |
| 30 mM | 0.1033 mL | 0.5165 mL | 1.0330 mL | 2.5825 mL | |
| 40 mM | 0.0775 mL | 0.3874 mL | 0.7748 mL | 1.9369 mL | |
| 50 mM | 0.0620 mL | 0.3099 mL | 0.6198 mL | 1.5495 mL | |
| 60 mM | 0.0517 mL | 0.2583 mL | 0.5165 mL | 1.2913 mL | |
| H2O | 80 mM | 0.0387 mL | 0.1937 mL | 0.3874 mL | 0.9685 mL |
| 100 mM | 0.0310 mL | 0.1550 mL | 0.3099 mL | 0.7748 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Powered by Bioz